Overview

Using Calcium Dobesilate to Treat Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy

Status:
Not yet recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

Summary

Calcium dobesilate has been recommended to treat diabetic retinopathy due to its potential in protecting against retinal vascular damage. However, there was limited evidence exploring its efficacy in combating diabetic retinopathy progression. This study, a single-blind, multicenter, cluster-randomized, controlled superiority trial, was designed to evaluate whether calcium dobesilate could prevent diabetic retinopathy progression into an advanced stage among Chinese patients with mild to moderate non-proliferative diabetic retinopathy.

Phase:

Phase 4

Details

Lead Sponsor:

Zhongda Hospital

Treatments:

Calcium
Calcium Dobesilate
Calcium, Dietary